Log in to your Inderes Free account to see all free content on this page.
Cinclus Pharma
20.5
SEK
+2.24 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+2.24%
+3.03%
-26.79%
-32.79%
-
-
-
-
-37.13%
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Read moreMarket cap
971.54M SEK
Turnover
1.47M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
20.2.
2025
Annual report '24
19.5.
2025
Interim report Q1'25
22.5.
2025
General meeting '24
ShowingAll content types
Issue and repurchase of class C shares
Cinclus Pharma agrees on pediatric study plan with FDA
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio